Treatments
Therapies, trials, approvals, and access.
AD-SMART, run from Imperial College London with Alzheimer's Research UK, has given its first doses in a trial that tests a repurposed ADHD drug and a repurposed diabetes drug against a single shared placebo group, at NHS sites from Cambridgeshire to Edinburgh.
Nine centres across North America are enrolling people whose dreams turn physical. There is no medicine in this study. Its purpose is to assemble the cohort that a future neuroprotection trial would need, and the scaffolding is the point.
Interim data from Arrowhead Pharmaceuticals show an experimental RNA interference drug cut a tau marker in spinal fluid by more than seventy percent in healthy volunteers, the first sign that a single injection can carry the company's delivery technology into the brain. Whether that drop in a marker means anything for Alzheimer's disease has not yet been tested.
Mission Therapeutics has dosed the first Parkinson's patient in a Phase 1b trial of MTX325, an oral drug designed to help brain cells clear out damaged mitochondria, a mechanism distinct from the amyloid and alpha-synuclein targets most other experimental drugs pursue, according to a new ClinicalTrials.gov registration and a company disclosure.
Sutter Health routed 447 anti-amyloid cases through a weekly remote panel so community neurologists could treat close to home. The published figures cover access and scan findings; cognitive benefit was not among them.
A two-year study of 197 lecanemab patients found that clearing amyloid from the brain does not look the same from one patient to the next. Their blood proteins split into three distinct trajectories, a finding that gives doctors a new way to think about why one person responds and another does not.
POLARIS-AD, a 1,535-person trial of the PDE5 inhibitor AR1001 in mild cognitive impairment and mild Alzheimer's dementia, has finished dosing. The company says topline results come in November. Until then, no one knows whether it works.
NestaCell, a therapy grown from the pulp of children's milk teeth, beat placebo on motor scores in a 35-person Brazilian study. The 120-person trial meant to confirm it is registered, unstarted on paper, and silent since 2023.
A funnel that began with 1,300 compounds ended with letrozole and irinotecan, and a memory test in mice carrying both amyloid and tau. NIH's new progress report flags the method. No one has tested the pair in a person with Alzheimer's.
A review published this month argues the field's next test is not wider gene expression but proof of dose, coverage in the right cells, primate validation and vector that can be made the same way twice.
uniQure has submitted a Biologics License Application for its one-time gene therapy AMT-130, asking the FDA for accelerated approval on the strength of 3-year data the agency had rejected as insufficient six months earlier.
A newly published World Dementia Council update lays out, for the first time in one document, how France's Haute Autorite de Sante turned down early-access reimbursement for both lecanemab and donanemab between September 2025 and May 2026, concluding neither cleared the bar for clinical benefit against cost.
A peer-reviewed report on the RETHINK-ALZ and REFOCUS-ALZ trials, published in the Journal of Prevention of Alzheimer's Disease, shows Cassava Sciences' oral drug candidate simufilam missed its co-primary, secondary and exploratory biomarker goals in both studies, closing out a Alzheimer's drug program that had drawn scientific scrutiny for years.
Denali's DNL593 was built to ferry progranulin past the blood-brain barrier. The Phase 1/2 study in GRN-related frontotemporal dementia is now fully enrolled at 40 participants, and the answer families want has slipped to 2027.
A statistics firm screened 6,044 records to re-read every Alzheimer's treatment trial since 1994. Its claim, presented as a conference abstract: some trials written off as failures show hints of benefit, and some hailed as promising look worse. What it does not do is put a number on the years lost.
A Phase I/II study of UX-DA003, an injectable stem cell product made by Shanghai's UniXell Biotechnology, has been listed on ClinicalTrials.gov, joining rather than departing from the field's stem-cell efforts.
A year after this newspaper tracked Europe's reversal on both anti-amyloid antibodies, the officials who assessed them have published a formal, citable account of the reasoning behind two different regulatory paths to the same restricted approval.
At a national neurosciences institute in Bengaluru, an exploratory randomized trial is adding a 180-day Ayurvedic regimen to optimized standard Parkinson's care, then measuring cortical excitability, heart-rate variability, cytokines and telomere length. The protocol is now published. The results are not.
New open-label data presented at AD/PD 2026 extend a four-year Nature Medicine finding on prasinezumab, but the comparisons rest on an external cohort, not a placebo group, as the drug moves into phase III testing.
A new analysis links the original ACTIVE trial, run in the late 1990s, to two decades of Medicare claims. Memory and reasoning training showed no effect on later dementia diagnosis; speed-of-processing training showed a reduced rate only among those who returned for booster sessions.
A 381-person Phase 2 trial of AL002, an antibody designed to activate the microglial receptor TREM2, ran its full course and did not slow decline in early Alzheimer's disease, according to a peer-reviewed report and the trial's public registration; developer Alector and partner AbbVie have since discontinued the study's long-term extension.
Peer reviewed 24 month data from a 12 person trial show sustained motor benefit from a single cell transplant, as a larger, sham controlled Phase 3 trial of the same therapy starts recruiting across three countries.
A single-author review of ClinicalTrials.gov counted every completed, results-posted trial of a treatment for sleep disturbance in Alzheimer's and dementia. The tally came to nine.
A peer-reviewed census of ClinicalTrials.gov registrations from 2015 to 2024 gives families a sourced map of what has actually been tested, including the handful of agents aimed at thinking and memory.
A clinical trials review from UCL's Huntington's Disease Centre has published the 36-month topline results for uniQure's gene therapy AMT-130, the same dataset the FDA has since agreed can support a US filing, along with the trial's fullest account yet of its limits.
A March 2026 paper written by members of the EU's own drug committee walks through the 210-day machinery behind the lecanemab and donanemab decisions. The record shows something more awkward than a split verdict: both antibodies were turned down, and both were rescued on appeal.
The company pulled its EU marketing authorisation application on 25 March 2026, before a re-examination it had requested was finished; the regulator's own question-and-answer document sets out why the oral sigma-1 agonist did not clear the bar.
Registry records show the worldwide half of Skyhawk Therapeutics' FALCON-HD programme recruiting since January, with the Australia and New Zealand study closed at 144 participants and up to 400 more sought. No placebo-controlled results exist yet.
The published record behind the adrabetadex application is a conference abstract reporting a 71 per cent lower risk of death against matched external controls, not a randomised trial. Hearing loss remains the known harm.
A US early access programme for Niemann-Pick disease type C, registered as NCT04316637, has produced four-year outcomes in 109 participants at 14 sites, 53 of them adults. Severity scores were reported as broadly stable, but nobody in the programme received a comparison treatment.
The CHMP found the efficacy evidence insufficient on 23 July 2026, two years after the same drug was approved in the United States. Zevra has asked for re-examination and is keeping its expanded access programme open.
After recommending against public funding in February, the Canadian Drug Expert Committee posted a draft in July recommending reimbursement with conditions and a substantial price cut. The recommendation is not binding, and no province has yet listed the drug.
The public record for TRAILRUNNER-ALZ 1 now lists Eli Lilly's subcutaneous antibody remternetug as a completed phase 3 study, but the home-injection findings behind the current interest exist so far only as conference material, and no results are published.
The UK register for TOP HAT lists the trial as recruiting with a final enrolment date of 31 July 2026, 15 months after its funder announced that an independent monitoring committee had told the team to stop taking new participants.
The zervimesine expanded access programme in dementia with Lewy bodies has run since June 2025 on donated money. Its registry record, now closed to new entrants, is a rare public look at how access works when nothing is approved.
SHIMMER randomly assigned 130 people with mild-to-moderate dementia with Lewy bodies and met only a safety endpoint. Every efficacy result was exploratory, including the 86 percent behavioural figure now shaping a pivotal trial that will not start until mid-2027.
Sarepta's SRP-1005 is being tested at two New Zealand sites in a Phase 1 study that measures safety and drug levels, not benefit. Dosing began in May.
REGEN4HD, registered as NCT07451613, is implanting embryonic stem cell-derived neural stem cells into the striatum of 21 people with early Huntington's. It is a safety study, and the field it grew out of is a long lesson in patience.
A 20-patient randomised crossover trial in Bologna found intranasal oxytocin reduced the misreading of faces as angry and cut self-focused speech, while the formal social cognition measures it was designed to move did not improve
A phase 1a study of VES001 in healthy volunteers, posted as a preprint on 31 March 2026, reports higher progranulin in blood and spinal fluid after seven days of twice-daily capsules. The same drug has since been given to six asymptomatic carriers of GRN mutations, the group whose disease an antibody with the same target failed to slow.